Tumors with BRCA1 and BRCA2 mutations have demonstrated increased susceptibility to PARP inhibitors given the tumor cells defects in chromosomal repair and error-free DNA double-stranded breaks [9]. This evidence concerns the gene BRCA1 and neoplasm.